Sean P. Nolan
Sean P. Nolan is a former chief executive of AveXis, the company behind the development of Zolgensma, a gene therapy for spinal muscular atrophy (SMA). He played a pivotal role in taking the company public and navigating the commercialization of the drug amidst rising scrutiny over drug pricing.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| United States | 1 | 5.00 | 0.02% | +0% | 331,002,651 | 58,543 | $21,000,000 | 3,714$ |
| Totals | 1 | 331,002,651 | 58,543 | $21,000,000 | 3,714$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
United States:
Sean P. Nolan was appointed as the CEO of AveXis after John Carbona and oversaw the company's IPO.
5